Bedtime
Community- Dose
- 100 mcg
- How often
- Once nightly
- How long
- 8–12 weeks, then about 4 off
Most cited. Taken fasted, 2–3 hours after the last meal, usually in the same shot as ipamorelin.
Draw 5 units5 mg + 2.5 mL
PreclinicalGHRH analog
CJC-1295 (no DAC)
Mod GRF 1-29
- Common dose
- 100 mcg, 1–3× daily
- Cycle
- 12 weeks on, 4 off
- Vial sizes
- 5 mg
- Typical draw
- 5 units5 mg with 2.5 mL, 100 mcg
A 29-amino-acid GHRH fragment with four amino acid swaps that slow its breakdown. It triggers a short pulse of growth hormone; its half-life is about 30 minutes.
Evidence. No published human trials of this exact peptide.
Status
- Approval
- Not approved as a drug in the US or EU.
- US compounding
- Nomination withdrawn, so no longer in FDA Category 2 (April 2026). In December 2024 FDA’s advisory committee voted 0 to 13 against adding it to the 503A bulks list (1 to 12 for the acetate form). Not on the July 2026 agenda.
- Sport (WADA 2026)
- Banned in sportS2.2.4 growth hormone releasing factors: GHRH and its analogues, with CJC-1295 named. Mod GRF 1-29 is a GHRH analogue. Banned at all times.
Category 2 is FDA’s list of bulk substances that may present significant safety risks in compounding. The 503A bulks list adds substances that pharmacies may compound with. Advisory committee votes are advice; FDA makes the final decision. Sport status follows the WADA Prohibited List in force since January 1, 2026; athletes should confirm with their anti-doping organization. Checked October 5, 2026. Status of every compound.
How it works
CJC-1295 without DAC is the first 29 amino acids of growth-hormone-releasing hormone (GHRH), the brain signal that tells the pituitary to release growth hormone, with four swaps meant to slow its breakdown. Like GHRH, it is expected to act on GHRH receptors on the pituitary and trigger short pulses of growth hormone. No study has tested this exact peptide: FDA found no pharmacology studies of it in 2024 and said results for the DAC version can’t be carried over.
AnimalMainly from cell and animal studies; not shown in people.
Not known
Whether it raises GH and IGF-1 in people, by how much and for how long, and what repeated daily use does have never been measured.
Protocol
Community
100 mcg per injection is most cited (range 50–300 mcg), 1–3× daily.
- Frequency
- 1–3× daily (bedtime most common)
- Route
- Subcutaneous injection
- Timing
- Fasted (2+ hours after food), often 30 minutes before bed. Usually paired with ipamorelin.
- Cycle
- 8–12 weeks on, about 4 weeks off.
12 weeks on, 4 off, shown over 26 weeks
Common protocols
The ways CJC-1295 (no DAC) is most often run, each tagged with where it comes from.
Split doses
Community- Dose
- 100 mcg
- How often
- 2–3 times daily
- How long
- 8–12 weeks
Fasted doses spread through the day, often including one at bedtime. Less common than bedtime only.
Draw 5 units5 mg + 2.5 mL
Taking it
Where it goes
Subcutaneous injection, rotating sites. Usually at bedtime on an empty stomach, 2–3 hours after the last meal.
If you miss a dose
No published guidance. Skip the missed dose and take the next one at the usual time; don’t double up.
What to expect
- Each dose
A short GH pulse. Half-life is about 30 minutes, so it doesn’t build up the way the DAC version does.
Community - Weeks to months
Better sleep, recovery and body composition are reported but untested; there are no human trials of this peptide.
Community
Side effects and what to do
Flushing or warmth after the shot
Commonly reported and usually brief. Stop if it comes with hives, swelling or trouble breathing.
Injection-site redness or rash
Rotate sites. Stop if a rash spreads beyond the site.
Water retention, joint or muscle aches
Linked to higher GH and IGF-1. Lower the dose or stop if it persists.
Headache or tiredness
Usually mild. Stop if severe or persistent.
Higher blood sugar
GH raises glucose. Check fasting glucose, especially with prediabetes or diabetes.
Stop and get medical help
Hives with face, lip or throat swelling, trouble breathing, chest pain, or fainting: stop and get emergency care.
Who should avoid it
No product label covers CJC-1295 (no DAC), so these come from human studies and from precautions based on how it works. Most important first.
- Anyone with active or past cancer
- PrecautionIt is designed to raise growth hormone and IGF-1, which promote cell growth, and FDA notes that mice making excess GHRH develop pituitary tumors. No study has tested this peptide.
- Diabetes or high blood sugar
- PrecautionGrowth hormone raises blood sugar, and FDA says the diabetes risk on growth hormone labels may also apply to drugs like this that raise GH. Its effect on blood sugar has never been measured.
- Pregnancy or breastfeeding
- PrecautionNo human safety data exist.
- Anyone relying on product quality
- PrecautionIt isn’t an approved drug, so vials have no regulated standard for identity, purity or sterility. FDA notes the names for the versions with and without DAC are used inconsistently.
Interactions
No interaction studies have been published, and no product label lists any.
Precaution: follows from how it works or from a related drug, and hasn’t been tested. This isn’t a complete list: a pharmacist or doctor can check a specific medicine or condition.
Tracking and pairing
Worth tracking
- IGF-1
- Fasting glucose
- Thyroid (TSH, free T4)
- Swelling or hand numbness
Often paired with
- Ipamorelin
The standard pairing: a GHRH analog plus a ghrelin-receptor agonist, often premixed. Never tested together in a published trial.
Human studies
No published human studies of CJC-1295 (no DAC) turned up in our October 2026 review. The evidence note at the top of this page sums up what is known.
Limits of the evidence
No published study has given this exact peptide to people or animals; FDA found none when it reviewed it in 2024. The human results often quoted for it come from CJC-1295 with DAC, a different, longer-acting molecule. The doses people inject, repeated daily use, long-term safety and product purity are all untested.
Mixing your vial
| Vial | Water | Common dose | Draw | Strength | Action |
|---|---|---|---|---|---|
| 5 mg | 2.5 mL | 100 mcg | 5 units (0.05 mL) | 2 mg/mL |
Dose chart
5 mg vialSyringe units for common doses at different water volumes. Select a cell to open it in the calculator.
| Dose | Water added | |||
|---|---|---|---|---|
| 1 mL | 2 mL | 2.5 mL | 3 mL | |
| 50 mcg | ||||
| 60 mcg | ||||
| 75 mcg | ||||
| 100 mcg | ||||
| 150 mcg | ||||
| 200 mcg | ||||
| 250 mcg | ||||
| 300 mcg | ||||
U-100 insulin syringe: 100 units is 1 mL. Draws over 100 units show in mL. Faded values are under 2 units, which is hard to measure. Check that your vial holds the larger volumes.
Datasheet
- Half-life
- No reliable value has been published.
- Type
- Peptide, 29 amino acids
- Molecular weight
- 3,367.9 g/mol
- Formula
- C152H252N44O42
- Sequence
- Y-(D-Ala)-DAIFTQSYRKVLAQLSARKLLQDILSR-NH2
- Storage before use
- Freezer (−20 °C) for long-term storage; fridge for short periods.
- After mixing or opening
- Fridge (2–8 °C); use within about 4 weeks.
- Molecule: PubChem CID 56841945
- Storage: Community Common practice; no approved label exists for this peptide
Every compound side by side: the half-life chart and the storage chart.
Cautions
- No human safety data for this exact peptide.
- Flushing, headache and injection-site reactions.
- Raises GH and IGF-1: avoid with active cancer. May worsen blood sugar control.
Questions
What is CJC-1295 (no DAC)?
A 29-amino-acid GHRH fragment with four amino acid swaps that slow its breakdown. It triggers a short pulse of growth hormone; its half-life is about 30 minutes.
How does CJC-1295 (no DAC) work?
CJC-1295 without DAC is the first 29 amino acids of growth-hormone-releasing hormone (GHRH), the brain signal that tells the pituitary to release growth hormone, with four swaps meant to slow its breakdown. Like GHRH, it is expected to act on GHRH receptors on the pituitary and trigger short pulses of growth hormone. No study has tested this exact peptide: FDA found no pharmacology studies of it in 2024 and said results for the DAC version can’t be carried over. Whether it raises GH and IGF-1 in people, by how much and for how long, and what repeated daily use does have never been measured.
Is CJC-1295 (no DAC) FDA-approved?
Not approved as a drug in the US or EU. Nomination withdrawn, so no longer in FDA Category 2 (April 2026). In December 2024 FDA’s advisory committee voted 0 to 13 against adding it to the 503A bulks list (1 to 12 for the acetate form). Not on the July 2026 agenda.
What is the usual CJC-1295 (no DAC) dose?
From community reports, not established: 100 mcg per injection is most cited (range 50–300 mcg), 1–3× daily. These are the amounts sources reference, not recommendations.
How much water do I mix CJC-1295 (no DAC) with?
There’s no single right amount, because the water only sets the strength. With 2.5 mL of bacteriostatic water in a 5 mg vial, the strength is 2 mg/mL, so 100 mcg is 5 units on a U-100 insulin syringe. More water makes small doses easier to measure. The dose chart above shows other volumes.
Who should avoid CJC-1295 (no DAC)?
No product label covers CJC-1295 (no DAC), so these come from human studies and from precautions based on how it works. Anyone with active or past cancer: It is designed to raise growth hormone and IGF-1, which promote cell growth, and FDA notes that mice making excess GHRH develop pituitary tumors. No study has tested this peptide. Diabetes or high blood sugar: Growth hormone raises blood sugar, and FDA says the diabetes risk on growth hormone labels may also apply to drugs like this that raise GH. Its effect on blood sugar has never been measured. Pregnancy or breastfeeding: No human safety data exist. The “Who should avoid it” section lists 1 more group.
How should CJC-1295 (no DAC) be stored?
Before mixing: Freezer (−20 °C) for long-term storage; fridge for short periods. After mixing: Fridge (2–8 °C); use within about 4 weeks. This is common practice; no product label covers it.
Is CJC-1295 (no DAC) banned in sport?
Yes. S2.2.4 growth hormone releasing factors: GHRH and its analogues, with CJC-1295 named. Mod GRF 1-29 is a GHRH analogue. Banned at all times.
Has CJC-1295 (no DAC) been studied in people?
No published human studies turned up in our October 2026 review. The evidence note at the top of this page sums up what is known.
Sources
- FDA briefing document: CJC-1295-related bulk drug substances, Pharmacy Compounding Advisory Committee (December 2024)
For the protocol details
- Public submission on CJC-1295 dosing and safety, FDA docket FDA-2024-N-4777
For how it works, who should avoid it and the limits of the evidence
- Jetté et al., design of CJC-1295 from GHRH 1–29, rat studies (Endocrinology 2005) PMID 15817669
Doses tagged Community come from public dosing guides and user reports, checked against at least two of them. Those sites aren’t named here because many of them sell peptides or earn commissions on them.